Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   60 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
MOMs-CMA, NCT03911466: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

Active, not recruiting
3
97
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
01/25
01/25
MOMs, NCT03918850: Medication Treatment for Opioid Use Disorder in Expectant Mothers

Active, not recruiting
3
140
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
01/25
01/25
MOMs-INO, NCT03911739: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

Recruiting
3
200
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
01/25
01/25
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26

Download Options